It is a modular urinalysis workflow launched by DIRUI, which can meet the realistic needs of clinical laboratories for automated and high-throughput urine testing.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Recently, Sysmex and Shanghai Pinnacles Medical Technology Co., Ltd. reached a strategic cooperation.

Element Biosciences and Bio-Rad on Wednesday announced a partnership to demonstrate the Bio-Rad SEQuoia RNA sequencing library preparation portfolio on the Element Aviti benchtop sequencer.

Roche announced on Thursday that it has expanded a previous collaboration with Janssen Biotech to create companion diagnostics for targeted therapies.

January-December 2022 results rose significantly, with net profit attributable to shareholders of the listed company amounting to CNY 1,720 million to 1,880 million, representing a year-on-year net profit growth of 101.84% to 120.62%.

Illumina, Inc. (Nasdaq: ILMN) today announced its financial results for the fourth quarter and fiscal year 2022, which include consolidated financial results for GRAIL.

Becton Dickinson announced on Wednesday that it has received Emergency Use Authorization from the US Food and Drug Administration for its combination COVID-19, influenza A/B, and respiratory syncytial virus test.

A-share listed Sinocare issued a full-year performance forecast. The Company expects a significant rise in January-December 2022 results, net profit attributable to shareholders of the listed company is CNY 400 million to 460 million, net profit increased by 271.85% to 327.63% year-on-year.

The US Food and Drug Administration in January modified existing 510(k) clearances for several firms, including Becton Dickinson and Roche, while it granted new clearances for diagnostic instruments and assays from Medica, Selux Diagnostics, and others, according to the agency website.

Qiagen reported on Tuesday that its fourth quarter sales declined 14 percent with an expected decrease in COVID-related sales offset by increased sales in the firm's non-COVID portfolio.

Assure Tech released a full-year earnings forecast, in which the company expects its January-December 2022 results to rise sharply, with net profit attributable to shareholders of the listed company amounting to CNY 2.895 to 3.378 billion, a net profit increase of 292.06% to 357.40% year-on-year.